Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations

Ming Mo Hou, Shiu Feng Huang, Han Pin Kuo, Cheng T.A. Yang, Ying Huang Tsai, Chih Teng Yu, Horng Chyuan Lin, Chih Hung Chen, Chih Liang Wang, Fu Tsai Chung, Jia Juan Hsieh, Todd Hsu, Hsin Yi Cheng, Li Ying Ou, Hung Ming Wang, Yung Chang Lin, Nai Jen Chang, John Wen Cheng Chang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Epidermal growth factor receptor (EGFR) positivity as assessed by chromogenic in situ hybridization (CISH) has been demonstrated to be associated with EGFR mutation status. This study was conducted to compare the responsiveness of CISH-positive and CISH-negative lung adenocarcinomas to erlotinib. Patients and Methods: Patients received erlotinib (150 mg/day) alone until disease progression or intolerable toxicity. EGFR gene status was examined by CISH. The response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity profiles were assessed. Results: Thirty-one patients underwent response evaluations and CISH analyses, 12 of whom harboured CISH-positive adenocarcinomas. The overall RR (p=0.035), median PFS (p=0.091) and median OS (p=0.408) were higher in the CISH-positive group. No difference in toxicity profiles was observed between these two groups. Conclusion: EGFR status as assessed by CISH can predict the response to erlotinib in patients with advanced lung adenocarcinoma.

Original languageEnglish
Pages (from-to)1107-1112
Number of pages6
JournalAnticancer Research
Volume32
Issue number3
Publication statusPublished - Mar 1 2012
Externally publishedYes

Keywords

  • Adenocarcinoma
  • Chromogenic in situ hybridization (CISH)
  • EGFR
  • Erlotinib
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations'. Together they form a unique fingerprint.

  • Cite this

    Hou, M. M., Huang, S. F., Kuo, H. P., Yang, C. T. A., Tsai, Y. H., Yu, C. T., Lin, H. C., Chen, C. H., Wang, C. L., Chung, F. T., Hsieh, J. J., Hsu, T., Cheng, H. Y., Ou, L. Y., Wang, H. M., Lin, Y. C., Chang, N. J., & Chang, J. W. C. (2012). Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and cish-negative EGFR gene alterations. Anticancer Research, 32(3), 1107-1112.